| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2010075542 |
| Title |
Cdk Inhibitors. |
| Abstract |
The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. |
| Applicant(s) |
Curis, Inc |
| Representative Drug(s) |
D0M5DX |
Drug Info
|
IC50 = 100 to 1000 nM |
[1] |
| Patent ID |
WO2009085185 |
| Title |
Fused Pyridine, Pyrimidine and Triazine Compounds As Cell Cycle Inhibitors. |
| Abstract |
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives. |
| Applicant(s) |
Amgen, Inc |
| Patent ID |
WO2009036016 |
| Title |
Cdk Inhibitors Containing A Zinc Binding Moiety. |
| Abstract |
The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors. |
| Applicant(s) |
Curis, Inc |
| Representative Drug(s) |
D0M5DX |
Drug Info
|
IC50 = 100 to 1000 nM |
[1] |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20107713994 |
| Title |
Anticancer Activity of Cyclin Dependent Kinase Inhibitors. |
| Representative Drug(s) |
D0W4MN |
Drug Info
|
IC50 = 1 nM |
[1] |
